Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | CA4 | P22748 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658251 | 0.75 | MEN1 (0.44) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL20149247 | 0.75 | MEN1 (0.44) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL19658253 | 0.75 | TSHR (0.42) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL12814045 | 0.75 | SIGMAR1 (0.34) | MEN1KMT2A | |
| SCHEMBL13558658 | 0.75 | — | — | |
| SCHEMBL12813711 | 0.75 | ITGB3 (0.36) | MEN1KMT2A | |
| SCHEMBL19224373 | 0.74 | CA2 (0.36) | MEN1KMT2APOLBCA12CA1 | |
| SCHEMBL24558857 | 0.74 | MEN1 (0.47) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL22198374 | 0.74 | TSHR (0.52) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL20149314 | 0.73 | TSHR (0.41) | MEN1KMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | MEN1 486/4885KMT2A 3995/4885POLB 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.